Abstract
Background
Pharmacovigilance, defined by the World Health Organisation as ‘the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem’ plays a key role in ensuring that patients receive safe drugs. Our knowledge of a drug’s adverse reactions can be increased by various means, including spontaneous reporting, intensive monitoring and database studies. New processes, both at a regulatory and a scientific level, are being developed with the aim of strengthening pharmacovigilance. On a regulatory level, these include conditional approval and risk management plans; on a scientific level, transparency and increased patient involvement are two important elements.
Objective
To review and discuss various aspects of pharmacovigilance, including new methodolgical developments.
Similar content being viewed by others
References
World Health Organisation Collaborating Centre for International Drug Monitoring (2007) The importance of pharmacovigilance. Available at http://www.who-umc.org. Cited 18 Dec 2007
Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102
Topol EJ (2004) Failing the public health–rofecoxib, Merck, and the FDA. N Engl J Med 351:1707–1079
Horton R (2004) Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 364:1995–1996
Hampton T (2005) Experts point to lessons learned from controversy over rofecoxib safety. JAMA 293:413–414
Krumholz HM, Ross JS, Presler AH et al. (2007) What have we learnt from Vioxx? Br Med J 334:120–123
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
Solomon DH, Winkelmayer WC (2007) Cardiovascular risk and the thiazolidinediones: deja vu all over again? JAMA 298:1216–1218
Hampton T (2007) MI risks linked to rosiglitazone. JAMA 298:1149–1151
Rosen CJ (2007) The rosiglitazone story–lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844–846
Krall RL (2007) Cardiovascular safety of rosiglitazone. Lancet 369:1995–1996
Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195
Home PD, Pocock SJ, Beck-Nielsen H et al (2007) Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis. N Engl J Med 357:28–38
European Medicines Agency (EMEA) (2007) European Medicines Agency confirms positive benefit–risk balance for rosiglitazone and pioglitazone. Available at http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf. Cited 18 Oct 2007
Information for healthcare professionals rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm. Cited 19 Nov 2007
Mangano DT, Tudor IC, Dietzel C (2006) The risk associated with aprotinin in cardiac surgery. N Engl J Med 354:353–365
European Medicines Agency (EMEA) (2007) European Medicines Agency recommends suspension for marketing authorisation of aprotinin-containing medicines for systemic use. Available at http://www.emea.europa.eu/pdfs/human/press/pr/53467807en.pdf. Cited 1 Feb 2008
Mitka M (2006) Report criticizes lack of FDA oversight. JAMA 296:920–922
Lenzer J (2004) FDA is incapable of protecting US “against another Vioxx”. Br Med J 329:1253
Ray WA, Stein CM (2006) Reform of drug regulation—beyond an independent drug-safety board. N Engl J Med 354:194–201
Furberg CD, Levin AA, Gross PA et al. (2006) The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 166:1938–1942
Avorn J (2007) Paying for drug approvals—who’s using whom? N Engl J Med 356:1697–1700
Strom BL (2006) How the US drug safety system should be changed. JAMA 295:2072–2075
Psaty BM, Charo RA (2007) FDA responds to institute of medicine drug safety recommendations—in part. JAMA 297:1917–1920
Baciu A, Stratton K, and Burke SP (eds) (2006) Committee on the Assessment of the US Drug Safety System The future of drug safety: promoting and protecting the health of the public. Institute of Medicine, Washington D.C.
Psaty BM, Burke SP (2006) Protecting the health of the public–Institute of Medicine recommendations on drug safety. N Engl J Med 355:1753–1755
European Medicines Agency (EMEA) (2006) Assessment of the European Community system of pharmacovigilance. Available at http://www.cbg-meb.nl/NL/docs/nieuws/rapp-fraunhofer.pdf. Cited 18 Dec 2007
Raine JM (2007) Risk management—a European regulatory view. In: Mann R, Andrews E (eds) Pharmacovigilance, 2nd edn. Wiley, Chichester
Gross CP, Mallory R, Heiat A et al. (2002) Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 137:10–16
Heiat A, Gross CP, Krumholz HM (2002) Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162:1682–1688
Zarin DA, Young JL, West JC (2005) Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol 40:27–35
Wardell WM, Tsianco MC, Anavekar SN et al. (1979) Postmarketing surveillance of new drugs: I. Review of objectives and methodology. J Clin Pharmacol 19:85–94
McBride WG (1961) Thalidomide and congenital malformations. Lancet 2:1358
van Grootheest K, Olsson S, Couper M et al. (2004) Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 13:457–464
van Grootheest K, de Jong-van den Berg (2004) Patients’ role in reporting adverse drug reactions. Expert Opin Drug Saf 3:363–368
van Grootheest AC, Passier JL, van Puijenbroek EP (2005) Direct reporting of side effects by the patient: favourable experience in the first year. Ned Tijdschr Geneeskd 149:529–533
Eland IA, Belton KJ, van Grootheest AC et al. (1999) Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 48:623–627
Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385–396
Edwards IR (1999) Spontaneous reporting—of what? Clinical concerns about drugs. Br J Clin Pharmacol 48:138–141
Clarke A, Deeks JJ, Shakir SA (2006) An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 29:175–181
Hauben M, Madigan D, Gerrits CM et al. (2005) The role of data mining in pharmacovigilance. Expert Opin Drug Saf 4:929–948
van Puijenbroek E, Diemont W, van Grooteest K (2003) Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 26:293–301
Bate A, Lindquist M, Edwards IR et al. (2002) A data mining approach for signal detection and analysis. Drug Saf 25:393–397
Szarfman A, Machado SG, O’Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 25:381–392
Mackay FJ (1998) Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf 19:343–353
Mann RD (1998) Prescription-event monitoring–recent progress and future horizons. Br J Clin Pharmacol 46:195–201
Coulter DM (1998) The New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf 7:79–90
Coulter DM (2000) The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf 9:273–280
Shakir SAW (2007) PEM in the UK. In: Mann R, Andrews E (eds) Pharmacovigilance, 2nd edn. Wiley, Chichester
European Commission Enterprise and Industry Directorate-general (2007) Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance. European Commission Enterprise and Industry, Brussels
Strom BL, (Ed) (2005). Pharmacoepidemiology, 4th edn. Wiley, Chichester
Gelfand JM, Margolis DJ, Dattani H (2005) The UK general practice research database. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester
Parkinson J, Davies S, Van Staa T (2007) The general practice research database: now and the future. In: Mann R, Andrews E (eds) Pharmacovigilance, 2nd edn. Wiley, Chichester
Wood L, Martinez C (2004) The general practice research database: role in pharmacovigilance. Drug Saf 27:871–881
Leufkens HG, Urquhart J (2005) Automated pharmacy record linkage in the Netherlands. In: Strom BL (ed) Pharmacoepidemiology. 4th edn. Wiley, Chichester
Sturkenboom MCJM (2007) Other databases in Europe for the analytic evaluation of drug effects. In: Mann R, Andrews E (eds) Pharmacovigilance, 2nd edn. Wiley, Chichester
Hugman B (2006) The Erice declaration: the critical role of communication in drug safety. Drug Saf 29:91–93
Adis International (2007) The Erice Manifesto: for global reform of the safety of medicines in patient care. Drug Saf 30:187–190
Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 12:17–29
European Medicines Agency (EMEA) (2007) European risk management strategy: achievements to date. Available at http://www.emea.europa.eu/pdfs/human/phv/30816707en.pdf. Cited 18 Dec 2007
European Medicines Agency (EMEA) (2007) Public status report on the implementation of the European risk management strategy. Available at http://www.emea.europa.eu/pdfs/human/phv/16895407en.pdf. Cited 18 Dec 2007
McClellan M (2007) Drug safety reform at the FDA–pendulum swing or systematic improvement? N Engl J Med 356:1700–1702
Coombes R (2007) FDA tightens its grip on drug regulation. Br Med J 334:290–291
Zwillich T (2007) US lawmakers tackle safety reforms at the FDA. Lancet 369:1989–90
Hennessy S, Strom BL (2007) PDUFA reauthorization—drug safety’s golden moment of opportunity? N Engl J Med 356:1703–1704
Sim I, Chan AW, Gulmezoglu AM et al. (2006) Clinical trial registration: transparency is the watchword. Lancet 367:1631–1633
European Medicines Agency (EMEA) (2005) Guideline on procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to article 14(8) of regulation (EC) NO 726/2004 Available at http://www.emea.europa.eu/pdfs/human/euleg/35798105en.pdf. Cited 18 Dec 2007
European Medicines Agency (EMEA) (2005) Guideline on risk management systems for medicinal products for human use. Available at http://www.emea.europa.eu/pdfs/human/euleg/9626805en.pdf. Cited 18 Dec 2007
van Grootheest K, de Graaf L, de Jong-van den Berg LT (2003) Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 26:211–217
de Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K (2008) Adverse drug reaction reporting by patients in the Netherlands: Three years of experience. Drug Saf 6:515–524
Härmark L, Kabel JS, van Puijenbroek EP, van Grootheest AC (2006) Web-based intensive monitoring, a new patient based tool for early signal detection (abstr). Drug Saf 29:911–1010
Pirmohamed M, Park BK (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22:298–305
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Härmark, L., van Grootheest, A.C. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 64, 743–752 (2008). https://doi.org/10.1007/s00228-008-0475-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-008-0475-9